Open Access

Association of invasion-promoting tenascin-C additional domains with breast cancers in young women

  • David S Guttery1,
  • Rachael A Hancox1,
  • Kellie T Mulligan2,
  • Simon Hughes2,
  • Sinead M Lambe1,
  • J Howard Pringle1,
  • Rosemary A Walker1,
  • J Louise Jones2 and
  • Jacqueline A Shaw1Email author
Breast Cancer Research201012:R57

https://doi.org/10.1186/bcr2618

Received: 23 March 2010

Accepted: 2 August 2010

Published: 2 August 2010

Abstract

Introduction

Tenascin-C (TNC) is a large extracellular matrix glycoprotein that shows prominent stromal expression in many solid tumours. The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated. The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.

Methods

Expression of AD1 and AD2 was related to hypoxanthine phosphoribosyltransferase 1 as a housekeeping gene in breast tissue using quantitative RT-PCR, and the results were related to clinicopathological features of the tumours. Constructs overexpressing an AD1-containing isoform (TNC-14/AD1/16) were transiently transfected into breast carcinoma cell lines (MCF-7, T-47 D, ZR-75-1, MDA-MB-231 and GI-101) to assess the effect in vitro on invasion and growth. Statistical analysis was performed using a nonparametric Mann-Whitney test for comparison of clinicopathological features with levels of TNC expression and using Jonckheere-Terpstra trend analysis for association of expression with tumour grade.

Results

Quantitative RT-PCR detected AD1 and AD2 mRNA expression in 34.9% and 23.1% of 134 invasive breast carcinomas, respectively. AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts. Although not tumour specific, AD1 and AD2 expression was significantly more frequent in carcinomas in younger women (age ≤40 years; P < 0.001) and AD1 expression was also associated with oestrogen receptor-negative and grade 3 tumours (P < 0.05). AD1 was found to be incorporated into a tumour-specific isoform, not detected in normal tissues. Overexpression of the TNC-14/AD1/16 isoform significantly enhanced tumour cell invasion (P < 0.01) and growth (P < 0.01) over base levels.

Conclusions

Together these data suggest a highly significant association between AD-containing TNC isoforms and breast cancers in younger women (age ≤40 years), which may have important functional significance in vivo.

Introduction

The role of the stromal microenvironment in modulating breast cancer behaviour is well established [1, 2]. A major modulatory component of the stromal environment is the extracellular matrix, and changes in extracellular matrix composition may therefore be expected to be a key factor in determining tumour behaviour. A consistent feature of the stroma around many breast carcinomas is upregulation of the extracellular matrix glycoprotein tenascin-C (TNC) [35].

TNC is a complex multifunctional protein that can influence cell behaviour directly and indirectly [6, 7]. It has been shown to promote cell migration [8], to inhibit focal adhesion formation [9], to induce cell proliferation [6] and in some cases to act as a cell survival factor [10]. TNC promotes angiogenesis [11] and can induce expression of matrix metalloproteinases [12], which themselves have been implicated in promoting tumour growth and invasion [13].

Structurally TNC comprises a linear arrangement of domains, with a cysteine-rich N-terminus followed by 14.5 epidermal growth factor-like repeats, a region of fibronectin type III-like repeats and a fibrinogen-like domain at the C-terminus (Figure 1) [14]. The structure and size of TNC varies as a result of alternative splicing of domains within the fibronectin type III repeat domain; exons 10 to 16 (domains A1 to A4, B, C and D) can undergo alternative splicing either singly or in combination. A number of biologically active sites have been mapped to the fibronectin type III repeat domain, including recognition sites for cell surface receptors such as integrins [15], cell adhesion molecules of the immunoglobulin superfamily [16], and annexin II [17] as well as sites susceptible to proteolytic cleavage by matrix metalloproteinases [18]. Inclusion or exclusion of different domains in this region can thus generate considerable functional diversity, and up to 22 human splice variants have been identified by RT-PCR analysis [19].
Figure 1

Schematic representation of tenascin-C. Protein structure illustrating the N-terminal tenascin assembly domain, the epidermal growth factor (EGF)-like repeat region, the fibronectin type III-like region and the C-terminal fibrinogen-like domain. Exon organisation is shown below (adapted from [25]). Note that the first exon of TNC is not translated and is shown in grey; therefore, exon number 1 in this figure is the first coding exon. UTR, untranslated region.

Changes in the profile of TNC isoforms expressed in tumours compared with normal tissue have been described. A switch from the small or truncated form of TNC, which lacks exons 10 to 16, to predominant expression of the large, full-length variant of TNC has been demonstrated in breast, lung and colorectal carcinoma [2022]. In glioblastoma, upregulation of an isoform containing exon 15 (domain C), which is rarely detected in normal tissues or malignant epithelium, has been demonstrated [23]. We previously identified induction of two intermediate-sized TNC isoforms in breast cancers [24] and showed that these isoforms can enhance tumour cell invasion [25]; a similar change was demonstrated in ovarian carcinomas [26]. Although the precise significance of altered TNC isoform expression is not well understood, it seems likely that different isoforms have distinct biological function, a concept supported in recent studies [25, 27].

Two less-studied repeat regions have been identified in human, mouse and avian TNC, termed additional domain (AD) 1 and AD2, inserted between domains B and C [2830]. Transcripts encoding AD1 have been detected in a variety of cancers [31], whilst inclusion of AD2 has so far been described only in oral squamous carcinomas [28]. Expression of both repeats has been detected in embryonic avian tissue. Interestingly, in situ hybridisation demonstrated that TNC-AD1 mRNA is abundant at sites of cell motility and branching morphogenesis, suggesting that inclusion of this repeat may contribute to the migration-promoting effect of TNC [31].

The potential to exploit tumour-specific, alternatively spliced isoforms as therapeutic targets has already been demonstrated [32]. The aims of the present study were therefore to establish whether TNC-AD1 and/or TNC-AD2 domains represent tumour-associated isoforms in breast cancer, to determine whether expression of these isoforms correlates with clinicopathological features and tumour subtypes identified by immunohistochemical profiling [33, 34], and to use in vitro studies to investigate the functional significance of a TNC isoform containing the AD1 domain to tumour cell behaviour. The results of the study show that TNC-AD domains are significantly associated with breast cancers in younger women (age <40 years), with high grade and with oestrogen receptor (ER)-negative status. Moreover, in vitro cell culture models show that, in some cell backgrounds, AD1-containing isoforms promote tumour cell invasion and growth at a higher level than that seen with vector controls and other TNC isoforms.

Materials and methods

Tissues and cells

Fresh and/or formalin-fixed tissue was obtained from patients undergoing breast surgery in accordance with Ethics Approval from Leicestershire Research Ethics Committee (06/Q2502/70) and North East London Research Ethics Committee (05/Q0403/199). Since all samples were anonymised there was no requirement from either research ethics committee for informed consent. For isolation of normal cells, tissue was obtained from women undergoing breast reduction surgery who gave informed consent (LNRREC 7054).

Two hundred and four samples were analysed from 155 carcinomas selected based on age (68 infiltrating ductal carcinomas from women aged ≤40 years, 62 infiltrating ductal carcinomas from women aged >40 years, 25 infiltrating lobular carcinomas from women aged >40 years), two cases of ductal carcinoma in situ, 14 benign breast lesions including fibroadenoma and fibrocystic change, and 33 normal breast samples from reduction mammoplasty procedures. Tissue was either snap-frozen in liquid nitrogen or routinely processed and paraffin-embedded following formalin fixation. In selected normal samples, tissue was processed and enzymatically digested to yield single-cell populations, and myoepithelial cells, luminal epithelial cells and fibroblast cells were isolated and characterised as described previously [35].

Breast cell lines (MCF-7, ZR-75-1, T47 D, Hs578T, MDA-MB-231, MDA-MB-468, MDA-MB-436, HBL-100 and MCF-10A) were obtained from American Type Culture Collection (Rockville, MD, USA). Most cell lines were maintained in DMEM plus 2 mM L-glutamine and 10% FBS. ZR-75-1 and MDA-MB-436 cell lines were maintained in RPMI supplemented with 10% FBS. The MCF-10A cell line was maintained in a 1:1 mixture of Ham's F12 (Invitrogen Life Science, Carlsbad, CA, USA) and DMEM, 2 mM glutamine supplemented with 5% heat-inactivated horse serum, insulin (10 μg/ml), hydrocortisone (0.5 μg/ml) and epidermal growth factor (20 ng/ml) (all SigmaGenosys, Dorset, UK).

Transfection of breast carcinoma cell lines

Breast cancer cell lines MCF-7, T-47 D, ZR-75-1, MDA-MB-231 and GI-101 were transiently transfected with a novel TNC-14/AD1/16 construct, generated by PCR ligation using previously generated plasmids (TNC-S, TNC-L, TNC-9/14/16) [25] and a Vector control (empty pCMV Script vector) and FuGene HD transfection reagent (Roche, Welwyn Garden City, UK) according to the manufacturer's protocol. For endogenously TNC-expressing cell lines, co-transfection with the pmaxGFP vector (Lonza, Slough, UK) was also performed to assess transfection efficiency. TNC expression was confirmed using immunohistochemistry for TNC-null cell lines. For all cell lines, expression was also confirmed by quantitative RT-PCR. Transfection efficiencies for each isoform were confirmed by estimating the proportion of cells that were either immunostained positive or were expressing green fluorescent protein (GFP).

RNA isolation and generation of cDNA

RNA was isolated from frozen tissue for 64 tumour samples, all benign and normal samples and 1 × 105 cells from each breast cell line using Tri-reagent (Sigma). Seventy tumour tissue samples were available from a previous study in which mRNA was isolated using oligo-dT-linked Dynabeads® (Dynal, Bromborough, UK). Total RNA (1 μg) or all bead-isolated mRNA was reverse transcribed at 42°C for 1 hour using Expand-RT (Boehringer Mannheim, Welwyn Garden City, UK) as described previously [24].

Quantitative polymerase chain reaction

Owing to limiting amounts of tissue, a nested quantitative PCR approach was devised to amplify TNC exons from frozen tissues. First-round PCR comprised 20 cycles of amplification with primers located in domain 4 (exon 8) and domain 7 (exon 18), to amplify the entire alternative spliced region of TNC (TNC 8/18). Taqman real-time PCR (Applied Biosystems, Foster, CA, USA) was then applied to survey different exons. Inventoried assays were available for the Tenascin-C invariant exon 17/18 boundary (Applied Biosystems Taqman Assay, Hs01115654_m1) and hypoxanthine phosphoribosyltransferase 1 (Applied Biosystems Taqman Assay, Hs99999909_m1) as a housekeeping gene. Primers and probes were developed in-house for AD1 and AD2 (Table 1). For the inventoried Taqman assays, 4 μl cDNA (diluted 1:10) was analysed in a reaction containing 0.5 μl probe, 0.5 μl ultra-pure H2O and 5 μl of 2 × Taqman Fast PCR mastermix. For the AD1 and AD2 assays, 3.6 μl cDNA (diluted 1:10) was analysed in a reaction containing 0.2 μl probe, 0.6 μl each primer and 5 μl of 2 × Taqman Fast PCR mastermix.
Table 1

Primer sequences for RT-PCR and asymmetric PCR

Primer

Sequence 5' to 3'

T8 - forward

CAATCCAGCGACCATCAACG

T18 - reverse

CGTCCACAGTTACCATGGAG

T16 - reverse

GTTGTCAACTTCCGGTTCGG

AD1 - forward

TGGTGGAGAACACTGGCTATGAC

AD1 - reverse

GGGATCCCCAGCCAAGGT

AD1-FAM-MGB

CAGTGTGGCAGGAAC

AD2 - forward

GATCACCCCCATGAGACCAT

AD2 - reverse

TGATGACAGAGCTGC GAGACA

AD2-FAM-MGB

TGCTGTCTGTGCCTGG

GAPDH - forward

AGAACATCATCCCTGCCTC

GAPDH - reverse

GCCAAATTCGTTGTCATACC

Actin antisense

TCATCACCATTGGCAATGAG

Actin sense

CTAGAAGCATTTGCGGTGGA

AD1 antisense

GAACCAAAGCCACAGTTGG

AD1 sense

TAATGACAAAGGCAGTGAG

Sense and antisense primers were used to generate single-stranded DNA probes for in situ hybridisation.

For all breast cell lines and a subset of the carcinomas (11 carcinomas in women aged ≤40 years and 11 carcinomas in women aged >40 years), AD1, AD2 and exon 17/18 were also assayed directly to enable evaluation of AD1 and AD2 expression relative to total TNC expression (exon 17/18). All quantitative PCR analysis was performed using Step-One qPCR software (Applied Biosystems). The number of cycles necessary to produce a product above background (Ct value) was recorded and, after normalisation to the Ct value for hypoxanthine phosphoribosyltransferase 1, the relative expression was determined with the following formula:
Relative expression = 2 ( Δ Δ Ct )

Determination of TNC transcript expression

The number of TNC transcripts was calculated using a standard curve generated from nested isoform-specific 8/18 PCR products. This was then used to calculate the number of molecules in a known concentration of sample. A log2 value was then produced from the mean Ct value and normalised against the mean Ct values for the endogenous controls.

Sequencing

AD1 amplicons were analysed by DNA sequencing. Products were sequenced from AD1-F and AD1-R primers, respectively (Table 1), using 1 μl Big Dye Terminator reactions (ABI, Beverley, UK) and analysed on an ABI Prism 377 DNA sequencer. Sequence profiles were analysed using the Chromas software (version 2.3; Technelysium Pty, Ltd Eden Prairie, MN, USA).

Immunohistochemistry

Immunohistochemistry for cytokeratin (CK) 14 (Sigma), CK5/6 (Sigma) and P-cadherin (BD Biosciences Cowley, UK) was performed on 4 μm formalin-fixed, paraffin-embedded (FFPE) serial sections from a subset of 96 breast carcinomas. A standard avidin-biotin complex technique was employed with citrate buffer microwave antigen retrieval for P-cadherin. Normal breast tissue was used as a positive control for all antibodies. Negative controls involved omission of the primary antibody. Sections were scored positive for CK14, CK5/6 or P-cadherin if >10% of the tumour cells were stained. The ER and progesterone receptor were examined in 138 tumour cases, and HER2 examined in 134 cases [36]. All interpretation was carried out by RAW and JLJ.

Western blotting

Levels of cellular and secreted TNC isoforms were determined by western blotting of transfected cell lysates and serum-free culture media respectively. Cells were transiently transfected and incubated for 24 hours, serum-free media was added and the culture media was collected a further 48 hours after transfection. Protein concentrations were quantified on a Lambda 25 UV/VIS spectrophotometer at 750 nm using the bovine serum albumin protein assay, and equal amounts of protein were loaded onto 6% SDS-PAGE gels and transferred to Hybond ECL nitrocellulose membrane (Amersham Biosciences, Little Chalfont, UK). Membranes were blocked in Tris-buffered saline, 5% milk and 1% Tween for 1 hour and were probed for 1 hour with a rabbit polyclonal TNC antibody (clone H300, recognising all forms of TNC; Santa-Cruz Biotechnology, Santa Cruz, CA, USA). A secondary antibody, donkey anti-rabbit horseradish peroxidase-linked IgG (1:2,000; Amersham Biosciences), was added for 1 hour and blots were detected using an enhanced chemiluminescence detection kit (Amersham Biosciences).

In situlocalisation of AD1-containing mRNA

Single-stranded sense and antisense AD1 and β-actin control DNA probes were synthesised using asymmetric PCR [24] with specific primers (Table 1) and incorporation of digoxigenin-11-dUTP. In situ hybridisation was carried out on 4 μm de-waxed rehydrated tissue sections as described previously [24]. The optimum probe concentration (200 to 500 ng/ml) was titrated to eliminate background staining, whilst retaining good signal strength. Negative controls used sense probes, RNase pretreatment of tissue sections and omission of the probe in the hybridisation protocol.

Analysis of tumour cell invasion

Measurement of tumour cell invasion was based on modified Boyden Chamber assays using the Fluoroblok tumour cell invasion system as described previously [37]. To measure the direct effect of TNC isoform expression on tumour cell invasion, transiently transfected cells were placed in the upper chamber of the assay and DMEM containing 10% (v/v) FCS was added to the lower chamber as a chemotactic stimulus - except for the MDA-MB-231 cell line, where DMEM containing 1% (v/v) FCS was used. Assays were monitored in real time up to 48 hours with readings every 2 hours and for a total of six replicates representing three separate transfections. Relative fluorescence to time 0 was used as a measure of invasion for each time point,

Analysis of tumour cell growth

The direct effects of TNC isoform expression on tumour cell growth were assessed using 4',6-diamidino-2-phenylindole staining of cell nuclei as described previously [38]. Tumour cells were transfected, and cultured for 48 hours in DMEM containing 10% (v/v) FCS. Cells were washed with PBS, fixed in cold acetone/methanol (1:1) for 2 minutes and washed twice with PBS. Cells were then stained using 4',6-diamidino-2-phenylindole (1:20,000) in PBS for 3 minutes and washed twice with PBS. Cell nuclei were examined using a fluorescence microscope and counted using an in-house software program provided by Dr AE Sayan (University of Leicester, UK) [38]. Each experiment was performed for a total of nine replicates representing three separate transfections.

Statistical analysis

Statistical analysis was performed using SPSS 16 (SPSS Inc, Chicago, Illinois, USA). Relationships between factors were measured using the nonparametric Mann-Whitney test, except for grade where Jonckheere-Terpstra trend analysis was applied. All tests were two-sided and P < 0.05 was considered significant. For functional assays, two-way analysis of variance was performed.

Results

Expression of TNC-AD1 and TNC-AD2 in breast cell lines and isolated cell populations

Nine breast cell lines and isolated normal breast myoepithelial cells and fibroblast cells were screened for expression of TNC 17/18 (an invariant exon boundary, present in all TNC splice variants), AD1 and AD2 by real-time quantitative PCR. TNC 17/18, AD1 and AD2 were absent from ER-positive MCF-7, ZR-75-1, and T-47 D cells (Table 2). Of the AD1-positive cell lines, MDA-MB-436, HBL-100 and primary normal myoepithelial cells expressed the highest levels (>400,000 molecules per 1 μg RNA). All AD1-positive cell lines and isolated breast cell populations also expressed AD2, but at lower levels. When AD1 and AD2 expression was related to levels of total TNC expression, HS578T, HBL100 and primary myoepithelial cells showed the highest percentages of AD1 (>25% total TNC) and HS578T and MCF10A cells showed the highest AD2 percentages (>5% total TNC).
Table 2

Relative expression of tenascin-C, AD1 and AD2 in cell lines and isolated normal breast cells

 

Number of TNC transcripts (×103)

% of total TNC transcripts

Cell line

Total TNC

AD1

AD2

AD1

AD2

ZR-75-1

0

0

0

0

0

T-47D

0

0

0

0

0

MCF-7

0

0

0

0

0

Hs578T

162.651

41.432

14.574

25.47

8.96

MDA-MB-231

1,293.947

44.383

23.821

3.43

1.84

MDA-MB-436

8,409.526

479.824

55.735

5.71

0.66

MDA-MB-468

984.727

89.74

28.784

9.11

2.92

GI-101

1,529.834

143.854

8.433

9.40

0.55

HBL-100

15,017.045

6,671.261

483.212

44.42

3.22

MCF-10A

91.37

7.399

6.933

8.10

7.59

Primary MEC

2,925.394

1,863.143

142.39

63.69

4.87

Primary fibroblasts

5398.821

87.867

98.044

1.63

1.82

Percentage expression of additional domain (AD) 1 and AD2 relative to the invariant exon 17/18 boundary, as a marker of total tenascin-C (TNC) expression, normalised to the hypoxanthine phosphoribosyltransferase 1 control in cell lines and isolated normal breast cells. MEC, myoepithelial cells.

Expression of TNC-AD1 and TNC-AD2 in breast tissues

RNA was successfully isolated from 134 carcinomas, all 14 benign breast tissue samples and 33 normal breast tissue samples, demonstrated by detection of GAPDH by manual PCR. All samples were then analysed by quantitative RT-PCR for expression of the invariant TNC exon 17/18 boundary (total TNC), AD1 and AD2. Total TNC was detected in all samples apart from two of the carcinomas. AD1 expression was demonstrated in 42 (31%) carcinomas, five benign breast tissues and 12 normal breast tissues (eight of which were from women aged <40 years). TNC-AD2 was less frequent than TNC-AD1, being detected in 31 (23.1%) carcinomas, four benign breast tissue samples and four normal breast samples. Nineteen carcinomas, one benign sample and one normal sample expressed both AD1 and AD2.

TNC-AD1 and TNC-AD2 expression in relation to clinicopathological features of carcinomas

When quantitative data were compared with clinicopathological features of the carcinomas, expression of AD1 was significantly associated with grade 3 tumours, ER-negative status and with younger patient age (≤40 years) (Table 3). AD2 expression was also significantly associated with younger patient age (Table 3). When the data were stratified by presence of exons only, 19 carcinomas were positive for both AD1 and AD2 - 16 of these were from women aged ≤40 years (P < 0.001; Figure 2), and the highest frequency of TNC-AD1-positive and TNC-AD2-positive tumours was seen in women aged between 31 and 35 years. Neither AD1 nor AD2 showed any association with lymph node status.
Table 3

Relationship between expression of total TNC, TNC-AD1 and TNC-AD2 and clinicopathological features of tumours

Clinicopathological feature

 

Total TNC

TNC-AD1

TNC-AD2

 

n

Mean Ct (95% CI)

P

Mean Ct (95% CI)

P

Mean Ct (95% CI)

P

Age

       

   ≤40 years

47

23.5 (21.8 to 25.3)

0.006

36.6 (35.4 to 37.7)

<0.001

37.7 (36.7 to 38.6)

0.001

   >40 years

87

26.5 (25.7 to 27.3)

 

38.7 (38.1 to 39.3)

 

39.1 (38.5 to 39.7)

 

Tumour type

       

   IDC

109

25.4 (24.4 to 26.4)

0.554

37.8 (37.2 to 38.4)

0.079

38.7 (38.2 to 39.2)

0.760

   ILC

25

25.6 (24.7 to 26.5)

 

38.6 (37.1 to 40.0)

 

38.3 (36.5 to 39.9)

 

Grade

       

   I

14

27.6 (25.9 to 29.4)

0.109

39.1 (37.9 to 40.3)

0.017

39.8 (39.3 to 40.2)

0.066

   II

63

25.7 (24.6 to 26.7)

 

38.3 (37.4 to 39.1)

 

38.7 (37.9 to 39.5)

 

   III

57

24.7 (23.2 to 26.1)

 

37.3 (36.4 to 38.2)

 

38.2 (37.4 to 39.0)

 

Lymph node

       

   Positive

63

25.4 (24.2 to 26.6)

0.802

37.9 (37.2 to 38.8)

0.978

38.8 (38.2 to 39.4)

0.900

   Negative

68

25.5 (24.4 to 26.7)

 

37.9 (37.1 to 38.8)

 

38.5 (37.7 to 39.3)

 

   Not known

3

      

Oestrogen receptor

       

   Positive

89

25.6 (24.6 to 26.5)

0.413

38.2 (37.6 to 38.9)

0.011

38.7 (38.1 to 39.3)

0.316

   Negative

31

24.1 (22.2 to 26.1)

 

36.7 (35.3 to 38.0)

 

38.1 (36.9 to 39.3)

 

   Not known

14

      

Progesterone receptor

      

   Positive

79

25.4 (24.5 to 26.4)

0.431

37.9 (37.2 to 38.4)

0.441

38.8 (38.2 to 39.3)

0.641

   Negative

36

24.5 (22.6 to 26.4)

 

37.6 (36.4 to 38.7)

 

38.1 (36.8 to 39.5)

 

   Not known

19

      

Her-2

       

   Positive

17

23.3 (20.5 to 26.2)

0.232

37.6 (35.9 to 39.3)

0.639

38.2 (36.6 to 39.8)

0.452

   Negative

81

25.1 (24.2 to 26.1)

 

37.8 (37.0 to 38.6)

 

38.7 (38.0 to 39.4)

 

   Not known

36

      

Basal 1

       

   Positive

23

24.3 (22.2 to 26.4)

0.605

36.9 (35.3 to 38.6)

0.170

38.4 (37.2 to 39.7)

0.746

   Negative

109

25.4 (24.5 to 26.3)

 

38.0 (37.4 to 38.7)

 

38.6 (37.9 to 39.1)

 

   Not known

2

      

Basal 2

       

   Positive

22

25.8 (23.1 to 28.4)

0.103

37.6 (35.9 to 39.4)

0.960

38.5 (37.3 to 39.6)

1.000

   Negative

51

23.2 (21.4 to 25.0)

 

37.6 (36.6 to 38.7)

 

38.5 (37.7 to 39.3)

 

   Not known

61

      

CI, confidence interval; Ct, number of cycles necessary to produce a product above background; IDC: infiltrating ductal carcinoma; ILC: infiltrating lobular carcinoma; TNC, tenascin-C.

Figure 2

Distribution of additional domain-positive and additional domain-negative breast carcinomas in relation to patient age. Number of carcinomas positive or negative for both additional domain AD (1) and AD2. Box contains cases within the lower and upper quartiles, and the line indicates median age. The whiskers connect the youngest and oldest patients that are not outliers; o, outliers; *, extreme values, defined as more than three box-lengths from the box. TNC, tenascin-C.

For 22 of the carcinomas (11 carcinomas in women aged ≤40 years, 11 carcinomas in women aged >40 years), AD1, AD2 and exon 17/18 were assayed directly. The total number of TNC molecules and transcripts containing AD1 was greater in carcinomas from younger women (Table 4). It was not possible to statistically analyse AD2 expression since only four samples were positive.
Table 4

Tenascin-C transcript levels in carcinomas stratified by age

  

Number of molecules

Mean

Age

Sample

Total TNC

TNC-AD1

TNC-AD2

Total TNC

TNC-AD1

TNC-AD2

≤40 years

T1

1,212,265

52,620

0

143,696,985

8,944,007

2,027,925

 

T2

99,024,132

1,567,084

0

(P = 0.005)

(P = 0.030)

 
 

T3

2,088,668

150,030

118,774

   
 

T4

958,188

58,137

0

   
 

T5

4,701,400

0

0

   
 

T6

14,962,216

0

0

   
 

T7

11,837,854

197,415

0

   
 

T8

339,673

0

0

   
 

T9

192,103,000

17,251,715

11,618,505

   
 

T10

1,100,396,396

79,107,073

10,569,893

   
 

T11

153,043,046

0

0

   

>40 years

T12

37,859,646

0

0

4,677,309

25,914

2,211

 

T13

208,821

37,702

24,325

   
 

T14

7,992,309

0

0

   
 

T15

66,360

7,451

0

   
 

T16

897,614

0

0

   
 

T17

73,244

0

0

   
 

T18

1,206,237

229,110

0

   
 

T19

168,882

9,045

0

   
 

T20

276,036

0

0

   
 

T21

6,970

1,746

0

   
 

T22

2,694,279

0

0

   

Normalised expression of tenascin-C (TNC) molecules in carcinomas from women aged ≤40 years and >40 years. Mann-Whitney tests were used to calculate P values.

TNC-AD1 and TNC-AD2 expression was also analysed in relation to the tumour subtype, as determined by immunohistochemical profiling [33, 34]. Nielsen and colleagues considered that lack of ER and HER2 and presence of epidermal growth factor receptor (HER1) and CK5/6 could identify basal-like carcinomas [34]. Carey and colleagues defined basal-like carcinomas as ER-negative, PR-negative, Her2-negative, CK5/6-positive and/or CK14-positive [33]. There has been debate as to whether triple-negative cancers (that is, ER-negative, PR-negative, HER2-negative) are the same as basal-like tumours [39]. Rakha and colleagues have recently proposed that CK5/6 and/or CK14 can be used to define basal-like carcinomas irrespective of the expression of the other markers [40]. We therefore chose to examine a range of putative basal markers (ER, PR, HER2, CK5/6, CK14, and P-cadherin [41]) and compared the expression of these with AD1and AD2 expression.

Immunohistochemical profiling and TNC-AD1/AD2 status was known in 132 cases (59 women aged ≤40 years and 73 women aged >40 years) for basal phenotype 1 defined as triple-negative tumours, and in 73 cases (44 women aged ≤40 years and 29 women aged >40 years) for basal phenotype 2 defined as CK5/6-positive and/or CK14-positive tumours. There was no significant relationship between TNC-AD1/AD2 status and either basal phenotype (Table 3). There was also no relationship between TNC-AD1/AD2 status and either HER-2 or P-cadherin expression (data not shown).

The AD1 domain is part of novel intermediate-sized TNC isoforms

Sequencing was carried out on two tumour samples that showed expression of two different-sized AD1-containing isoforms (Figure 3a), the largest of which was tumour specific. Blast sequence analysis confirmed that AD1 was located within one of two different intermediate-sized TNC transcripts between exons 9/14 and either exons 15/16 or exon 16 alone (Figure 3b; sequence of AD1 [GenBank:EU295718]) [42]. Neither isoform contained AD2. Analysis of normal breast cell populations isolated from reduction mammoplasties demonstrated a single-isoform TNC-14/AD1/16 in myoepithelial cell populations from five separate donors and in five out of 12 fibroblast populations.
Figure 3

Identification of two distinct additional domain-1-containing tenascin-C isoforms. (a) RT-PCR analysis in two breast cancers using T8-F and AD1-R primers (Tracks 1 and 2) and using AD1-F and T16-R primers (Tracks 3 and 4). B, blank lane; L, ladder. (b) Two alternatively spliced isoforms identified by sequencing, shown schematically.

TNC-AD1 is derived largely from epithelial cells

In situ hybridisation was carried out on eight breast carcinomas with known TNC-AD1 status using TNC-AD1 probes and β-actin as a control (Figure 4). Specificity of signal was established using sense probes, which were consistently negative. Two carcinomas, which were negative for TNC-AD1 by quantitative RT-PCR, were also negative by in situ hybridisation. In six TNC-AD1-positive breast carcinomas, the TNC-AD1 antisense probe localised to tumour cells and not to stromal cells (Figure 4a); and in the associated myoepithelial cells around large histologically normal ducts, there was a lower level of expression detected (Figure 4b).
Figure 4

In situ localisation of tenascin-C additional domain 1 to tumour cells and normal myoepithelial cells. (a) An example of infiltrating ductal carcinoma positive for tenascin-C additional domain 1 (TNC-AD1) by RT-PCR: (i) H & E; (ii) in situ hybridisation using antisense probe to the TNC-AD1 domain, demonstrating signal in tumour cells; (iii) ISH using TNC-AD1 sense probe as a negative control. (b) A normal breast duct with adjacent tumour cells within a lymphovascular space: (i) H & E; (ii) ISH with antisense probe to TNC-AD1 showing signal in scattered myoepithelial cells of normal ducts as well as localised to tumour cells; (iii) ISH with TNC-AD1 sense probe as a negative control.

Direct effects of TNC isoforms on invasion and growth

Although the exon 15-containing isoform (TNC-14/AD1/15/16) was successfully cloned, it was not expressed at the protein level (as determined by western blotting - see Additional file 1) and therefore functional studies focused on the TNC-14/AD1/16 isoform. Transient transfection was used to determine the direct effects of TNC isoforms (TNC-S, TNC-9/14/16, TNC-14/AD1/16) on invasion in the three TNC null cell lines (MCF-7, T-47 D, ZR-75-1) and in two cell lines with endogenous TNC expression (MDA-MB-231 and GI-101) (Figure 5). All cell lines transfected with TNC-S showed no significant increase in invasion compared with vector controls. TNC-14/AD1/16-transfected MCF-7, T-47 D, MDA-MB-231 and GI-101 cells showed increased invasion over vector controls, which became significant with increasing time (Table 5). No significant increase in invasion was evident in the ZR-75-1 cell line.
Table 5

Analysis of cell invasion following transient transfection with tenascin-C isoforms

  

Cell line

Isoform

Time (hours)

MCF-7

T-47D

MDA-MB-231

GI-101

ZR-75-1

TNC-S

12

NS

NS

NS

NS

NS

 

24

NS

NS

NS

NS

NS

 

36

NS

NS

NS

NS

NS

 

48

NS

NS

NS

NS

NS

TNC-9/14/16

12

NS

NS

NS

NS

NS

 

24

NS

NS

NS

NS

NS

 

36

P <0.05 (NS)

NS (NS)

NS (NS)

P < 0.05 (<0.05)

NS (NS)

 

48

P < 0.001 (<0.05)

NS (NS)

NS (NS)

P < 0.001 (0.05)

NS (NS)

TNC-14/AD1/16

12

NS

NS

NS

NS

NS

 

24

P < 0.05 (NS)

P < 0.05 (NS)

P < 0.01 (NS)

NS (NS)

NS (NS)

 

36

P < 0.001 (<0.001)

P < 0.001 (<0.001)

P < 0.001 (<0.01)

NS (NS)

NS (NS)

 

48

P < 0.001 (<0.001)

P < 0.001 (<0.001)

P < 0.001 (<0.001)

P < 0.01 (NS)

NS (NS)

Significance at 12-hour intervals relative to vector-only controls (relative to TNC-S). NS, not significant.

Figure 5

Direct effects of tenascin-C isoform expression on tumour cell invasion. (a) Monitoring tumour cell invasion in real time using a modified Boyden chamber assay in (i) MCF-7, (ii) T-47 D, (iii) MDA-MB-231 and (iv) GI-101 cell lines transfected with three different TNC isoform constructs and the vector control; and (v) invasion of MCF-7 cells transfected with TNC-L and TNC-14/AD1/16 constructs. In all cases, data points represent the mean of six replicates representing three separate transfections; error bars shown. (b) Quantitative RT-PCR of total TNC transcripts (exons 17/18) from cells transfected with TNC constructs.

TNC-9/14/16-transfected MCF-7 and GI-101 cells also showed increased invasion over vector controls with time. No significant increase in invasion was observed in T-47 D, ZR-75-1 or MDA-MB-231 cell lines (Figure 5 and Table 5). A similar trend in invasion was observed when compared with TNC-S; however, significance appeared at a later time point (Table 5). In MCF-7 cells we also compared mean invasion induced by TNC-14/AD1/16 and TNC-L (this isoform contains all of the exons in the alternatively spliced region, with the exception of AD1 and AD2). TNC-14/AD1/16 significantly enhanced tumour cell invasion over cells expressing TNC-L (P < 0.001) (Figure 5a:v). Quantitative RT-PCR analysis of transfected TNC expression showed equivalent levels between constructs in all cell lines - except in MCF-7 cells, which showed TNC-S to be expressed at a higher level (Figure 5b).

Transient transfection was also used to determine the direct effects of TNC isoforms (TNC-S, TNC-9/14/16, TNC-14/AD1/16) on cell growth in MCF-7, T-47 D and MDA-MB-231 cells. A significant increase in cell number was observed 48 hours post transfection in both MCF-7 and MDA-MB-231 cells overexpressing TNC-9/14/16 and TNC-14/AD1/16 (P < 0.01 and P < 0.001, respectively, for MCF-7 cells; P < 0.001 for both isoforms in MDA-MB-231 cells) compared with the vector control. Furthermore, a significant increase was observed in MCF-7 cells overexpressing TNC-S (P < 0.01). No significant increase was observed in MDA-MB-231 cells overexpressing TNC-S. MDA-MB-231 cells overexpressing TNC-9/14/16 and TNC-14/AD1/16, however, showed a significant increase in cell numbers compared with TNC-S (P < 0.001 for both). No significant differences were found between isoforms and vector controls for T-47 D cells (Figure 6).
Figure 6

Direct effect of tenascin-C isoform expression on tumour cell growth. (a) Growth of MCF-7, MDA-MB-231 and T-47 D cell lines transfected with three different tenascin-C (TNC) constructs and a vector control. Bars represent the mean relative cell count compared with 0 hours, with each assay performed three times in triplicate; error bars shown. (b) Images of cells transfected with three different TNC constructs. Images were taken using a 4× magnification in exactly the same position in each well. **P < 0.01, ***P < 0.001.

Discussion

The TNC isoforms containing AD1 and/or AD2 have been suggested to be tumour specific [28, 31], and TNC-AD1 may contribute to a motility-promoting environment [30]. The present study has shown that expression of only one AD1-containing variant (TNC-14/AD1/15/16) was cancer specific, but higher mRNA levels of all AD1 and AD2 variants were associated with high-grade, ER-negative breast cancers, and cancers arising in younger women. Detection of AD2-containing isoforms was less frequent and at lower levels; we therefore focused on determining the functional significance of AD1 variants and showed that the TNC-14/AD1/16 isoform promoted invasion and growth.

The present study analysed a series of breast cancer cell lines and also isolated cell populations from normal breast (n > 5). Quantitative RT-PCR demonstrated expression of TNC-AD1 and TNC-AD2 isoforms in all TNC-positive lines, which were also ER-negative and were characterised by aggressive behaviour [4345]. Analysis of isolated cell populations from normal breast showed that the predominant source of AD1 and AD2 expression is the myoepithelium. Isolated stromal fibroblasts, the source of most TNC isoforms [24], showed only low-level expression that was not detected for AD1 by in situ hybridisation. The HBL-100 cell line also showed a high level of expression, and this exhibits myoepithelial cell characteristics [46]. AD1 was not detectable in normal tissues by in situ hybridisation; but was detected at a low level in isolated enriched populations of a single normal cell type. For the breast cancers, the cells expressing AD1 were predominantly malignant epithelial cells rather than fibroblasts. Sequencing of the two AD1 variants identified in cancers, with AD1 incorporated into an isoform containing exons 15 plus 16 or exon 16 alone, are distinct from those described by Mighell and colleagues [28]. In their study of oral tissues, AD1-containing isoforms were identified in normal and reactive lesions as well as tumour tissue, with TNC-AD2 expression rare but tumour specific. In the present study, the TNC-14/AD1/15/16 variant was cancer specific as this was not detected in any of the normal tissues or isolated cell populations.

We demonstrated that the TNC-14/AD1/16 isoform significantly increased breast cancer cell invasion and growth. The largest TNC isoform (TNC-L) has been frequently associated with an invasive phenotype [6, 9, 27], as have two other prominent isoforms containing exons 16 and 14/16 [24, 25]. The TNC-14/AD1/16 isoform showed a much greater effect on tumour cell invasion than TNC-L in MCF-7 cells, however, suggesting that these intermediate-sized isoforms may be most biologically relevant. TNC-14/AD1/16 also produced a greater effect than the TNC-9/14/16 isoform, but this was only significant for MCF-7 and T-47 D cells. The fully truncated TNC isoform (TNC-S) showed no significant effect on tumour cell invasion, consistent with previous reports [25].

The TNC-14/AD1/16 isoform was also shown to increase cell growth in MCF-7 cells at a similar level to isoform TNC-9/14/16, supporting our previous data [26]. In cells that endogenously express TNC (that is, MDA-MB-231), however, transfection with TNC-14/AD1/16 had a much greater effect on cell growth. The precise mechanisms leading to increased cell invasion and growth in the breast are unclear. Ruiz and colleagues [47] and Lange and colleagues [48] have associated triggering of glioma cell migration with a simultaneous mechanism of competitive inhibition of syndecan-4 binding of fibronectin and signalling by lysophosphatidic acid and platelet-derived growth factor (reviewed in [49]). Furthermore, TNC has been shown to be susceptible to degradation by matrix metalloproteinases [50, 51], which can reveal cryptic sites present in the TNC molecule [52] - of which AD1 could be a potential site. Further work using peptide fragments containing AD1 could help elucidate these functions.

High expression of either AD1-containing or AD2-containing mRNA in breast cancers was significantly associated with young patient age (≤40 years). AD1 expression was also associated with lack of ER and grade 3 tumours, both of which are features of cancers in younger women. These results correlate with findings by Helleman and colleagues, who suggested that high TNC expression could be an indirect marker for a defective ER pathway due to an inverse correlation between TNC mRNA and ER protein expression [53]. Breast carcinomas in young women exhibit a particularly aggressive phenotype compared with tumours arising in postmenopausal women [5456]. This may in part be attributed to the greater frequency of high-grade tumours in young women [57]. There is evidence that tumours in young women are biologically distinct, however, being associated with poorer survival independent of tumour grade and stage [58] and showing a higher frequency of loss of heterozygosity compared with grade-matched and stage-matched postmenopausal cancers [59]. The association of AD1 and AD2 expression with younger age supports the hypothesis that these tumours are biologically distinct.

Over recent years there has been increasing recognition of a subgroup of breast carcinomas characterised by high levels of expression of genes and proteins normally associated with the myoepithelial or basal cell population of the breast [33, 34, 36, 60]. This basal tumour subtype exhibits a poorer prognosis than other subgroups [60], occurs with high frequency in BRCA1-mutated tumours [36] and occurs more frequently in younger women [60]. To address whether the TNC-AD1 (myoepithelial-associated) and TNC-AD2 isoforms were associated with basal features, we compared TNC-AD1 status with expression of putative basal markers [33, 34]. There was no association of TNC-AD1 expression with either the triple-negative or CK 5/6-positive and/or CK14-positive subtypes, or with any of the other putative basal markers. This may be due to relatively small numbers of basal cases available for analysis, but a larger study was precluded by the need for fresh tissue for analysis.

Conclusions

The present study has shown a highly significant association between expression of TNC-AD1 and TNC-AD2 and carcinomas arising in young women (≤40 years), and TNC-AD1 is sometimes incorporated into a novel tumour-associated TNC isoform not detected in normal tissues. The association of TNC-AD1 expression with tumours arising in young women and also with high-grade and ER-negative tumours make it a plausible target for development of novel therapies. Functional studies showed that the TNC-14/AD1/16 isoform can significantly increase breast cancer cell invasion and growth, to a greater extent than the previously described tumour-associated TNC-9/14/16 isoform. This raises interesting questions regarding the functional significance of TNC isoforms containing the AD domains.

Abbreviations

AD: 

additional domain

CK: 

cytokeratin

Ct: 

number of cycles necessary to produce a product above background

ER: 

oestrogen receptor

DMEM: 

Dulbecco's modified Eagle's medium

FBS: 

foetal bovine serum

FFPE: 

formalin-fixed: paraffin-embedded

GFP: 

green fluorescent protein

H & E: 

haemotoxylin and eosin

PBS: 

phosphate buffered saline

PCR: 

polymerase chain reaction

RT: 

reverse transcriptase

TNC: 

tenascin-C

TNC-9/16: 

tenascin-C with only exon 16 of variable region

TNC-9/14/16: 

tenascin-C with only exons 14 and 16 of variable region

TNC-14/AD1/16: 

tenascin-C with only exons 14: AD1 and 16 of variable region

TNC-L: 

tenascin-C largest splice variant

TNC-S: 

tenascin-C fully truncated splice variant.

Declarations

Acknowledgements

The authors thank Mrs L Primrose for support with cloning of all TNC constructs and Dr AE Sayan for support with cell growth assays. DSG was funded by a doctoral training account from the Medical Research Council. RAH was funded by the Breast Cancer Campaign and the University of Leicester. KTM was funded by Cancer Research UK.

Authors’ Affiliations

(1)
Department of Cancer Studies and Molecular Medicine, University of Leicester, Infirmary Close, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary
(2)
Tumour Biology Laboratory, Cancer Research UK Clinical Cancer Centre, Institute of Cancer Studies, Queen Mary's School of Medicine and Dentistry

References

  1. Radisky DC, Bissell MJ: Cancer. Respect thy neighbor!. Science. 2004, 303: 775-777. 10.1126/science.1094412.View ArticlePubMedGoogle Scholar
  2. Roskelley CD, Bissell MJ: The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol. 2002, 12: 97-104. 10.1006/scbi.2001.0417.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002, 38: 2362-2370. 10.1016/S0959-8049(02)00210-1.View ArticlePubMedGoogle Scholar
  4. Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, Haglund C, Nevanlinna H, Blomqvist C: Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer. 1998, 78: 1507-1513.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Jones PL: Extracellular matrix and tenascin-C in pathogenesis of breast cancer. Lancet. 2001, 357: 1992-1994. 10.1016/S0140-6736(00)05133-3.View ArticlePubMedGoogle Scholar
  6. Chung CY, Murphy-Ullrich JE, Erickson HP: Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell. 1996, 7: 883-892.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Ghert MA, Qi WN, Erickson HP, Block JA, Scully SP: Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. Cell Struct Funct. 2001, 26: 179-187. 10.1247/csf.26.179.View ArticlePubMedGoogle Scholar
  8. Phillips GR, Krushel LA, Crossin KL: Domains of tenascin involved in glioma migration. J Cell Sci. 1998, 111: 1095-1104.PubMedGoogle Scholar
  9. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M: Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol. 1991, 115: 1127-1136. 10.1083/jcb.115.4.1127.View ArticlePubMedGoogle Scholar
  10. Cowan KN, Jones PL, Rabinovitch M: Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 2000, 105: 21-34. 10.1172/JCI6539.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Schenk S, Chiquet-Ehrismann R, Battegay EJ: The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. Mol Biol Cell. 1999, 10: 2933-2943.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Tremble P, Chiquet-Ehrismann R, Werb Z: The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell. 1994, 5: 439-453.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999, 98: 137-146. 10.1016/S0092-8674(00)81009-0.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Jones PL, Jones FS: Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol. 2000, 19: 581-596. 10.1016/S0945-053X(00)00106-2.View ArticlePubMedGoogle Scholar
  15. Prieto AL, Edelman GM, Crossin KL: Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc Natl Acad Sci USA. 1993, 90: 10154-10158. 10.1073/pnas.90.21.10154.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Weber P, Ferber P, Fischer R, Winterhalter KH, Vaughan L: Binding of contactin/F11 to the fibronectin type III domains 5 and 6 of tenascin is inhibited by heparin. FEBS Lett. 1996, 389: 304-308. 10.1016/0014-5793(96)00609-6.View ArticlePubMedGoogle Scholar
  17. Chung CY, Erickson HP: Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol. 1994, 126: 539-548. 10.1083/jcb.126.2.539.View ArticlePubMedGoogle Scholar
  18. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L: Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 1995, 270: 8650-8654. 10.1074/jbc.270.15.8650.View ArticlePubMedGoogle Scholar
  19. Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC: Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci. 1998, 39: 1135-1142.PubMedGoogle Scholar
  20. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L: Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1992, 52: 688-692. 10.1002/ijc.2910520504.View ArticlePubMedGoogle Scholar
  21. Dueck M, Riedl S, Hinz U, Tandara A, Moller P, Herfarth C, Faissner A: Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer. 1999, 82: 477-483. 10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
  22. Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H: Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol. 1999, 189: 475-480. 10.1002/(SICI)1096-9896(199912)189:4<475::AID-PATH462>3.0.CO;2-V.View ArticlePubMedGoogle Scholar
  23. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L: Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol. 1999, 154: 1345-1352.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC: Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res. 2002, 62: 3289-3297.PubMedGoogle Scholar
  25. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL: Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res. 2009, 11: R24-10.1186/bcr2251.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Wilson KE, Langdon SP, Lessells AM, Miller WR: Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer. 1996, 74: 999-1004.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T: Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol. 2003, 162: 1857-1867.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Mighell AJ, Thompson J, Hume WJ, Markham AF, Robinson PA: Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Int J Cancer. 1997, 72: 236-240. 10.1002/(SICI)1097-0215(19970717)72:2<236::AID-IJC6>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
  29. Sriramarao P, Bourdon MA: A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices. Nucleic Acids Res. 1993, 21: 163-168. 10.1093/nar/21.1.163.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Tucker RP, Spring J, Baumgartner S, Martin D, Hagios C, Poss PM, Chiquet-Ehrismann R: Novel tenascin variants with a distinctive pattern of expression in the avian embryo. Development. 1994, 120: 637-647.PubMedGoogle Scholar
  31. Derr LB, Chiquet-Ehrismann R, Gandour-Edwards R, Spence J, Tucker RP: The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation. 1997, 62: 71-82. 10.1046/j.1432-0436.1997.6220071.x.View ArticlePubMedGoogle Scholar
  32. Brack SS, Silacci M, Birchler M, Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res. 2006, 12: 3200-3208. 10.1158/1078-0432.CCR-05-2804.View ArticlePubMedGoogle Scholar
  33. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.View ArticlePubMedGoogle Scholar
  34. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.View ArticlePubMedGoogle Scholar
  35. Jones JL, Shaw JA, Pringle JH, Walker RA: Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol. 2003, 201: 562-572. 10.1002/path.1483.View ArticlePubMedGoogle Scholar
  36. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005, 11: 5175-5180. 10.1158/1078-0432.CCR-04-2424.View ArticlePubMedGoogle Scholar
  37. Partridge J, Flaherty P: An in vitro FluoroBlok tumor invasion assay. J Vis Exp. 2009, pii: 1475-Google Scholar
  38. Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, Mellon JK, Tulchinsky E: Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell. 2007, 18: 4615-4624. 10.1091/mbc.E07-05-0406.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS: Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res. 2007, 9: 404-10.1186/bcr1827.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO: Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007, 50: 434-438. 10.1111/j.1365-2559.2007.02638.x.View ArticlePubMedGoogle Scholar
  41. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD: Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005, 11: 4003-4011. 10.1158/1078-0432.CCR-04-2064.View ArticlePubMedGoogle Scholar
  42. NCBI Blast. [http://blast.ncbi.nlm.nih.gov/Blast.cgi]
  43. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10: 515-527. 10.1016/j.ccr.2006.10.008.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP: Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res. 1992, 52: 5190-5197.PubMedGoogle Scholar
  45. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992, 150: 534-544. 10.1002/jcp.1041500314.View ArticlePubMedGoogle Scholar
  46. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL: Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer. 2003, 106: 8-16. 10.1002/ijc.11172.View ArticlePubMedGoogle Scholar
  47. Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-Ehrismann R, Orend G: Growth promoting signaling by tenascin-C [corrected]. Cancer Res. 2004, 64: 7377-7385. 10.1158/0008-5472.CAN-04-1234.View ArticlePubMedGoogle Scholar
  48. Lange K, Kammerer M, Saupe F, Hegi ME, Grotegut S, Fluri E, Orend G: Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res. 2008, 68: 6942-6952. 10.1158/0008-5472.CAN-08-0347.View ArticlePubMedGoogle Scholar
  49. Midwood KS, Orend G: The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009, 3: 287-310. 10.1007/s12079-009-0075-1.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Cai M, Onoda K, Takao M, Kyoko IY, Shimpo H, Yoshida T, Yada I: Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res. 2002, 8: 1152-1156.PubMedGoogle Scholar
  51. Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y: Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett. 1994, 352: 216-218. 10.1016/0014-5793(94)00960-0.View ArticlePubMedGoogle Scholar
  52. Saito Y, Imazeki H, Miura S, Yoshimura T, Okutsu H, Harada Y, Ohwaki T, Nagao O, Kamiya S, Hayashi R, Kodama H, Handa H, Yoshida T, Fukai F: A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem. 2007, 282: 34929-34937. 10.1074/jbc.M705608200.View ArticlePubMedGoogle Scholar
  53. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM: Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008, 14: 5555-5564. 10.1158/1078-0432.CCR-08-0555.View ArticlePubMedGoogle Scholar
  54. Adami HO, Malker B, Holmberg L, Persson I, Stone B: The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986, 315: 559-563. 10.1056/NEJM198608283150906.View ArticlePubMedGoogle Scholar
  55. Chung M, Chang HR, Bland KI, Wanebo HJ: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996, 77: 97-103. 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
  56. Walker RA, Lees E, Webb MB, Dearing SJ: Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer. 1996, 74: 1796-1800.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Pillers EM: Histological grade of breast cancer in younger women. Lancet. 1992, 339: 1483-10.1016/0140-6736(92)92079-U.View ArticlePubMedGoogle Scholar
  58. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A: Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993, 341: 1039-1043. 10.1016/0140-6736(93)92407-K.View ArticlePubMedGoogle Scholar
  59. Johnson SM, Shaw JA, Walker RA: Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer. 2002, 98: 205-209. 10.1002/ijc.10197.View ArticlePubMedGoogle Scholar
  60. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14: 1368-1376. 10.1158/1078-0432.CCR-07-1658.View ArticlePubMedGoogle Scholar

Copyright

© Guttery et al.; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.